BP
UTHR icon

Broadleaf Partners’s United Therapeutics UTHR Stock Holding History

Broadleaf Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.11M Buy
13,117
+4,133
+46% +$2.33M 1.38% 29
2026
Q1 		$5.33M Sell
8,984
-298
-3% -$148K 1.24% 28
2025
Q4 		$4.52M Sell
9,282
-43
-0.5% -$20K 0.95% 33
2025
Q3 		$3.91M Sell
9,325
-165
-2% -$55.5K 0.82% 35
2025
Q2 		$2.73M Sell
9,490
-8
-0.1% -$2.39K 0.6% 42
2025
Q1 		$2.93M Sell
9,498
-189
-2% -$64.8K 0.77% 41
2024
Q4 		$3.42M Sell
9,687
-58
-0.6% -$21.3K 0.8% 36
2024
Q3 		$3.49M Buy
+9,745
New +$3.29M 0.83% 36

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Broadleaf Partners's UTHR Position: Q2 2026 in Review

Broadleaf Partners increased its United Therapeutics (UTHR) stake by 46% in Q2 2026, buying an estimated $2.33M and bringing the position to 13,117 shares worth $7.11M. The position accounts for 1.38% of the portfolio, ranked #29.

Broadleaf Partners first reported a position in UTHR in Q3 2024 and has held it in 8 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Broadleaf Partners held 13,117 shares of United Therapeutics worth $7.11M as of Q2 2026.
  • Broadleaf Partners bought 4,133 United Therapeutics shares in Q2 2026, an estimated $2.33M.
  • United Therapeutics made up 1.38% of Broadleaf Partners's portfolio in Q2 2026, its #29 holding.
  • Broadleaf Partners first reported a position in United Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Broadleaf Partners's 13F filing for Q2 2026, filed 13 Aug 2026.